← Back to contracts

Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)

US National Institutes of Health (NIH / NIDA) grant open #RFA-DA-26-056
Response due Dec 03, 2027 · 00:00 UTC

Summary

This NIH funding opportunity (RFA-DA-26-056) seeks to accelerate substance use research by leveraging existing datasets rather than collecting new primary data. The R21 mechanism supports exploratory/developmental research projects. Clinical trials are explicitly not allowed under this announcement. The opportunity is issued by the National Institute on Drug Abuse (NIDA) under HHS-NIH and remains open for applications through December 2027.

What they want

Technical requirements
  • Must use existing data — no new primary data collection permitted
  • Clinical trials are explicitly not allowed
  • R21 exploratory/developmental research mechanism applies
  • Must align with NIDA substance use research priorities

How they evaluate

Submission: Grants.gov federal grants portal (electronic submission)

Risks & flags

  • Multi-year open window (2024–2027) with rolling submissions is common for NIH RFAs but should be confirmed against published receipt dates in the full FOA
  • No dollar value or award ceiling stated in the synopsis — applicants should consult the full FOA for budget limits typical of R21 awards (~$275K direct costs over 2 years)

Market context

inferred from NAICS
Professional, Scientific & Technical Services
NAICS 541711
US market size
$2.0T
Typical award
$25K – $50M
Typical buyers
All federal civilianDoDStates
Commonly required
8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Accelerating the Pace of Substance Use Res…
Due Dec 03
Onboard ↗